Results 201 to 210 of about 776,039 (330)

Risk-benefit evaluation in approval of traditional and innovative drugs

, 2003
Rashmi R. Shah
openalex   +1 more source

An enzyme‐linked immunosorbent assay (ELISA)‐based activity assay for AMP‐activated protein kinase (AMPK)

FEBS Open Bio, EarlyView.
Measuring AMP‐activated protein kinase (AMPK) activity in vitro is crucial for testing AMPK activators or inhibitors with therapeutic potential. Here, we report an enzyme‐linked immunosorbent assay (ELISA)‐based AMPK activity assay with simple steps and high sensitivity, which offers a simple, robust, and cost‐effective alternative to traditional ...
Trezze P. Nguyen, Shangze Lyu, Yang Liu
wiley   +1 more source

Critical insights into the evolving drug-approval process in China. [PDF]

Cancer
Nikanjam M, Kurzrock R.
europepmc   +1 more source

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels. [PDF]

Ther Innov Regul Sci, 2021
Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Lassen AB, Morant AV.   +4 more
europepmc   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

FEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik, Deniz Bakkalci, Alexander J. MacRobert, Umber Cheema   +3 more
wiley   +1 more source

Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns. [PDF]

Clin Cancer Res
Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N.   +6 more
europepmc   +1 more source

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens [PDF]

, 2008
Ruthann M. Giusti, Kaushikkumar A. Shastri, Anne M. Pilaro, Chana Fuchs, Ruth Cordoba-Rodriguez, Kallappa M. Koti, Mark Rothmann, Angela Men, Hong Zhao, Monica Hughes, Patricia Keegan, Karen D. Weiss, Richard Pazdur   +12 more
openalex   +1 more source

Hydrophobicity causes anomalous migration of cystine/glutamate antiporter SLC7A11 in SDS‐PAGE with low acrylamide concentration

FEBS Open Bio, EarlyView.
SLC7A11 frequently migrates faster in SDS‐PAGE. The present study found that the high hydrophobicity of SLC7A11 causes its anomalous migration in SDS‐PAGE with a low concentration of acrylamide gel. Replacing isoleucine with asparagine reduced hydrophobicity and restored its normal migration at 55 kDa, revealing the role of hydrophobicity and gel ...
Nsengiyumva Emmanuel, Qian He, Yixin Kang, Dianbao Zhang, Min Gao, Minglin Wang, Kexin Fan, Jingwen Xiong, Shaobo Wu, Botao Fa, Zhengtao Xiao, Yingfang Niu, Jun Yao, Yilei Zhang   +13 more
wiley   +1 more source

Making Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information. [PDF]

Med Decis Making
Dijk SW, Krijkamp E, Kunst N, Labrecque JA, Gross CP, Pandit A, Lu CP, Visser LE, Wong JB, Hunink MGM.   +9 more
europepmc   +1 more source

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology. [PDF]

J Adv Pract Oncol, 2020
Kurtin SE, Taher R.
europepmc   +1 more source